Abstract
Thyroid gland presents a wide spectrum of tumours derived from follicular cells that range from well differentiated, papillary and follicular carcinoma (PTC and FTC, respectively), usually carrying a good prognosis, to the clinically aggressive, poorly differentiated (PDTC) and undifferentiated thyroid carcinoma (UTC). It is usually accepted that PDTC and UTC occur either de novo or progress from a pre-existing well differentiated carcinoma through a multistep process of genetic and epigenetic changes that lead to clonal expansion and neoplastic development. Mutations and epigenetic alterations in PDTC and UTC are far from being totally clarified. Assuming that PDTC and UTC may derive from well differentiated thyroid carcinomas (WDTC), it is expected that some PDTC and UTC would harbour genetic alterations that are typical of PTC and FTC. This is the case for some molecular markers (BRAF and NRAS) that are present in WDTC, PDTC and UTC. Other genes, namely P53, are almost exclusively detected in less differentiated and undifferentiated thyroid tumours, supporting a diagnosis of PDTC or, much more often, UTC. Thyroid-specific rearrangements RET/PTC and PAX8/PPARγ, on the other hand, are rarely found in PDTC and UTC, suggesting that these genetic alterations do not predispose cells to dedifferentiation. In the present review we have summarized the molecular changes associated with the two most aggressive types of thyroid cancer.
Keywords: telomerase, PI3K, β-catenin, undifferentiated thyroid carcinoma, BRAF, RAS, Poorly differentiated thyroid carcinoma, P53, Genetic Alterations, WNT PATHWAY
Current Genomics
Title: Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Volume: 12 Issue: 8
Author(s): Paula Soares, Jorge Lima, Ana Preto, Patricia Castro, Joao Vinagre, Ricardo Celestino, Joana P. Couto, Hugo Prazeres, Catarina Eloy, Valdemar Maximo and M. Sobrinho-Simoes
Affiliation:
Keywords: telomerase, PI3K, β-catenin, undifferentiated thyroid carcinoma, BRAF, RAS, Poorly differentiated thyroid carcinoma, P53, Genetic Alterations, WNT PATHWAY
Abstract: Thyroid gland presents a wide spectrum of tumours derived from follicular cells that range from well differentiated, papillary and follicular carcinoma (PTC and FTC, respectively), usually carrying a good prognosis, to the clinically aggressive, poorly differentiated (PDTC) and undifferentiated thyroid carcinoma (UTC). It is usually accepted that PDTC and UTC occur either de novo or progress from a pre-existing well differentiated carcinoma through a multistep process of genetic and epigenetic changes that lead to clonal expansion and neoplastic development. Mutations and epigenetic alterations in PDTC and UTC are far from being totally clarified. Assuming that PDTC and UTC may derive from well differentiated thyroid carcinomas (WDTC), it is expected that some PDTC and UTC would harbour genetic alterations that are typical of PTC and FTC. This is the case for some molecular markers (BRAF and NRAS) that are present in WDTC, PDTC and UTC. Other genes, namely P53, are almost exclusively detected in less differentiated and undifferentiated thyroid tumours, supporting a diagnosis of PDTC or, much more often, UTC. Thyroid-specific rearrangements RET/PTC and PAX8/PPARγ, on the other hand, are rarely found in PDTC and UTC, suggesting that these genetic alterations do not predispose cells to dedifferentiation. In the present review we have summarized the molecular changes associated with the two most aggressive types of thyroid cancer.
Export Options
About this article
Cite this article as:
Soares Paula, Lima Jorge, Preto Ana, Castro Patricia, Vinagre Joao, Celestino Ricardo, P. Couto Joana, Prazeres Hugo, Eloy Catarina, Maximo Valdemar and Sobrinho-Simoes M., Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas, Current Genomics 2011; 12 (8) . https://dx.doi.org/10.2174/138920211798120853
DOI https://dx.doi.org/10.2174/138920211798120853 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Biochemical Markers of Renal Function
Current Medicinal Chemistry MicroRNAs as Biomarkers for Birth Defects
MicroRNA Histone Deacetylase Inhibitors and Papillary Thyroid Cancer
Current Pharmaceutical Design VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Dietary Polyphenols and Type 2 Diabetes: Current Insights and Future Perspectives
Current Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy The Effects of Soy Isoflavones in Postmenopausal Women: Clinical Review
Current Drug Therapy Targeting microRNAs in Pathological Hypertrophy and Cardiac Failure
Mini-Reviews in Medicinal Chemistry Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Mitochondrial Uncoupling and the Regulation of Glucose Homeostasis
Current Diabetes Reviews Vitamin D Metabolism Genes in Asthma and Atopy
Mini-Reviews in Medicinal Chemistry A Review on Expedient Assets of Polymers Employed in Novel Topical Formulation for Successful Treatment of Arthritis
Current Applied Polymer Science Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Distinctive Phenotype Identification for Breast Cancer Genotypes Among Hereditary Breast Cancer Mutated Genes
Current Bioinformatics The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Identification of Inhibitors Based on Molecular Docking: Thyroid Hormone Transmembrane Transporter MCT8 as a Target
Current Drug Discovery Technologies